Previous 10 | Next 10 |
Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer PR Newswire – Invitae retrospective analysis reinforces the clinical actionability of following the ASBrS guidelines – ...
Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics PR Newswire - Sponsor of the Heart of Genetic Counseling program and award, recognizing excellence in patient care - - These studies co...
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization PR Newswire – First-of-its-kind authorization provides potential marketing differentiation and opportunities for largest testing category – – Testament to Invitae's product and l...
2023-10-02 16:20:56 ET Shares of Invitae (NYSE: NVTA) roared as much as 37% higher early Monday, then settled to trade up 13% as of 3 p.m. ET after the U.S Food and Drug Administration (FDA) authorized marketing efforts by Invitae for its groundbreaking gene-based test for cancer ri...
2023-10-02 10:04:07 ET DENVER, Colo., Oct 2, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Icecure Medical Ltd (NASDAQ: ICCM), Femasys (NASDAQ: FEMY), AERWINS Technologies (NASDAQ: AWIN), Invitae (NYSE:...
2023-10-02 06:46:21 ET More on Invitae Invitae: Revenue Troubles Build Invitae Corporation (NVTA) Q2 2023 Earnings Call Transcript Invitae Corporation 2023 Q2 - Results - Earnings Call Presentation Invitae names Ana Schrank as CFO Invitae receives NYS...
2023-09-25 16:34:41 ET More on Invitae Seeking Alpha’s Quant Rating on Invitae Historical earnings data for Invitae Financial information for Invitae Invitae: Revenue Troubles Build Invitae Corporation (NVTA) Q2 2023 Earnings Call Transcript ...
Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO PR Newswire SAN FRANCISCO , Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as ...
2023-09-22 16:36:54 ET More on Invitae Seeking Alpha’s Quant Rating on Invitae Invitae Is Treading In Competitive Waters Invitae touts results of trial for prostate cancer genetic testing Invitae appoints new interim CFO as Gorjanc moves back to previo...
Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard PR Newswire SAN FRANCISCO , Sept. 22, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it received a noti...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...